Updates in the Diagnosis of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system, and accurate diagnosis remains essential to ensuring timely intervention, preventing disability, and optimizing long-term patient outcomes. With the release of the 2024 McDonald Diagnostic Criteria updates, clinicians now have a more refined framework to diagnose MS earlier, more accurately, and with greater confidence. These updates emphasize the integration of imaging, clinical presentation, and biomarkers to reduce misdiagnoses and ensure that patients with accurate MS receive appropriate treatment without unnecessary delay.

This course provides a comprehensive and clinically practical review of the 2024 diagnostic changes. Learners will understand how dissemination in time (DIT) and dissemination in space (DIS) are now better supported through imaging criteria, the role of cortical lesions, updates on oligoclonal bands, and more explicit guidance on radiologically isolated syndrome (RIS) and clinically isolated syndrome (CIS). The activity breaks down the diagnostic process step-by-step using real-world examples that reflect typical neurology practice.

Participants will also learn how these changes influence initial treatment decisions, including when to initiate disease-modifying therapy (DMT), how early diagnosis affects prognosis, and how updated criteria may alter treatment selection for patients with clinically isolated presentations. By the end of this CME activity, clinicians will be equipped with the knowledge to confidently apply the 2024 McDonald updates to their patient population and improve diagnostic precision in MS care.

Educational Objectives

After completing this activity, learners will be able to:

• Identify the key changes in the 2024 updates to the McDonald Diagnostic Criteria for Multiple Sclerosis (MS).
• Apply the updated MS diagnostic criteria to patients evaluated in neurology practice.
• Discuss how diagnostic updates influence early treatment decisions for individuals with MS.
• Differentiate between CIS, RIS, and early MS using the revised clinical and imaging standards.

Who Should Do This Course?

• Clinicians who evaluate patients with suspected MS, CIS, or RIS.
• Neurology providers integrating the 2024 McDonald Criteria into diagnostic workflows.
• Practitioners making early disease-modifying therapy (DMT) decisions.
• Providers managing patients with unexplained neurological symptoms or demyelinating events.
• Healthcare professionals seeking updated guidance on distinguishing MS from mimics.

Did You Know?

• MS is the leading non-traumatic cause of disability in young adults, affecting nearly 2.8 million people worldwide.(Lancet Neurology, 2020)
• Early treatment with high-efficacy DMTs reduces relapse rates by up to 50–70% compared to delayed initiation.(JAMA Neurology, 2021)
• Oligoclonal bands are present in over 85–95% of MS cases, making them one of the strongest supportive biomarkers for diagnosis.(Neurology, 2022)
• Cortical lesions are now recognized as highly specific for MS, improving diagnostic accuracy compared to white matter lesions alone.(Brain, 2020)
• Radiologically isolated syndrome converts to clinical MS in ~50% of patients within 10 years.(Annals of Neurology, 2019)
• With improved MRI sequences, up to 40% more cortical and juxtacortical lesions can be detected, strengthening the dissemination in space (DIS) assessment.(Multiple Sclerosis Journal, 2021)

The estimated time to complete this activity is 1 hour.